RxSight RXST 深 沪
已收盘 10-23 16:00:00 美东时间
5.02
-0.060
-1.18%
华盛通- 最 高5.105
- 今 开5.07
- 成交量 32.68万股
- 最 低 5.01
- 昨 收 5.08
- 总市值 2.09亿
- 52周最高 13.22
- 市盈率 静 --
- 换手率 0.79%
- 52周最低 4.40
- 委 比 93.38%
- 总股本 4159.33万
- 历史最高 66.54
- 量 比 0.51
- 振 幅 1.87%
- 历史最低 4.40
- 每 手 1
- 风险率 2.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
RxSight, Inc. announced it will report third-quarter 2026 financial results after market close on November 3, 2026. Management will discuss the results during a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Participants can join by dialing (800) 715-9871 or (646) 307-1963 and entering conference code 8782462, or via the company’s investor relations website. RxSight, an ophthalmic medical device company, specializes in customized vision solution...
10-20 20:05
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
RxSight, Inc. announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy to strengthen its commercial leadership team and accelerate adoption of its Light Adjustable Lens™ (LAL™) technology. Conway brings over 20 years of experience in eye care, pharmaceuticals, and medical aesthetics, while Shields has over 30 years of ophthalmology leadership experience. ...
10-19 13:00
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5
B of A Securities analyst Craig Bijou maintains RxSight (NASDAQ:RXST) with a Underperform and lowers the price target from $6.5 to $5.5.
09-22 19:11
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
RxSight, Inc. announced that its management will participate in the Wells Fargo Healthcare Conference on September 9, 2026, in Boston. A live and archived webcast of the presentation will be available on the company’s investor relations website. RxSight, an ophthalmic medical device company, specializes in providing customized vision solutions after cataract surgery using its Light Adjustable Lens system, which allows doctors to customize patient...
08-26 20:15
RxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors
Rxsight, Inc. ($RXST) announced an update on their ongoing clinical study. The ...
08-13 00:30
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.
08-07 03:39
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. granted stock options and restricted stock units (RSUs) to its new CEO, Aziz Mottiwala, totaling 571,286 shares and 2,312,138 shares, respectively. The stock options have an exercise price of $5.19 per share, vesting 25% after one year and monthly thereafter. The RSUs vest 20% after one year, 20% after two years, and 60% after three years. The awards were granted under the 2026 Inducement Equity Incentive Plan to induce Mr. Mottiwal...
07-26 20:00
